Skip to main content

Stribild FDA Approval History

FDA Approved: Yes (First approved August 27, 2012)
Brand name: Stribild
Generic name: cobicistat, elvitegravir, emtricitabine and tenofovir
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

Development timeline for Stribild

DateArticle
Aug 27, 2012Approval FDA Approves New Combination Pill Stribild for HIV Treatment
May 11, 2012FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV
Dec 25, 2011U.S. FDA Accepts New Drug Application for Gilead's Once-Daily, Single-Tablet Quad HIV Regimen
Oct 28, 2011Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen

See also

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer